tetano
Editor, Senior Moderator
Viruses
. 2020 Jun 13;12(6):E642.
doi: 10.3390/v12060642.
Potential Antiviral Options Against SARS-CoV-2 Infection
Aleksandr Ianevski[SUP] 1 [/SUP], Rouan Yao[SUP] 1 [/SUP], Mona H?ys?ter Fenstad[SUP] 2 3 [/SUP], Svetlana Biza[SUP] 1 [/SUP], Eva Zusinaite[SUP] 4 [/SUP], Tuuli Reisberg[SUP] 5 [/SUP], Hilde Lysvand[SUP] 1 [/SUP], Kirsti L?seth[SUP] 1 [/SUP], Veslem?y Malm Landsem[SUP] 1 [/SUP], Janne Fossum Malmring[SUP] 2 [/SUP], Valentyn Oksenych[SUP] 1 [/SUP], Sten Even Erlandsen[SUP] 1 [/SUP], Per Arne Aas[SUP] 1 [/SUP], Lars Hagen[SUP] 1 [/SUP], Caroline H Pettersen[SUP] 1 [/SUP], Tanel Tenson[SUP] 4 [/SUP], Jan Egil Afset[SUP] 1 2 [/SUP], Svein Arne Nordb?[SUP] 1 2 [/SUP], Magnar Bj?r?s[SUP] 1 [/SUP], Denis E Kainov[SUP] 1 4 [/SUP]
Affiliations
Abstract
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
Keywords: antiviral drug combinations; antivirals; broad-spectrum antivirals.
. 2020 Jun 13;12(6):E642.
doi: 10.3390/v12060642.
Potential Antiviral Options Against SARS-CoV-2 Infection
Aleksandr Ianevski[SUP] 1 [/SUP], Rouan Yao[SUP] 1 [/SUP], Mona H?ys?ter Fenstad[SUP] 2 3 [/SUP], Svetlana Biza[SUP] 1 [/SUP], Eva Zusinaite[SUP] 4 [/SUP], Tuuli Reisberg[SUP] 5 [/SUP], Hilde Lysvand[SUP] 1 [/SUP], Kirsti L?seth[SUP] 1 [/SUP], Veslem?y Malm Landsem[SUP] 1 [/SUP], Janne Fossum Malmring[SUP] 2 [/SUP], Valentyn Oksenych[SUP] 1 [/SUP], Sten Even Erlandsen[SUP] 1 [/SUP], Per Arne Aas[SUP] 1 [/SUP], Lars Hagen[SUP] 1 [/SUP], Caroline H Pettersen[SUP] 1 [/SUP], Tanel Tenson[SUP] 4 [/SUP], Jan Egil Afset[SUP] 1 2 [/SUP], Svein Arne Nordb?[SUP] 1 2 [/SUP], Magnar Bj?r?s[SUP] 1 [/SUP], Denis E Kainov[SUP] 1 4 [/SUP]
Affiliations
- PMID: 32545799
- DOI: 10.3390/v12060642
Abstract
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
Keywords: antiviral drug combinations; antivirals; broad-spectrum antivirals.